In vitro Models of the Human Blood–Brain Barrier and the Impact of Efflux Transporters on Neurological Disorders: The Work of Cioni et al. (2012) by Vogelgesang, Silke & Jedlitschky, Gabriele
PSYCHIATRY
FRONTIERS COMMENTARY
published: 16 September 2014
doi: 10.3389/fpsyt.2014.00128
In vitro models of the human blood–brain barrier and the
impact of efflux transporters on neurological disorders: the
work of Cioni et al. (2012)
SilkeVogelgesang1* and Gabriele Jedlitschky 2
1 Department of Neuropathology, Institute of Pathology, University of Greifswald, Greifswald, Germany
2 Department of Pharmacology, Center of Drug Absorption andTransport (C_DAT), University of Greifswald, Greifswald, Germany
*Correspondence: sivogelg@uni-greifswald.de
Edited by:
Barry Boland, University College Cork, Ireland
Reviewed by:
Barry Boland, University College Cork, Ireland
Shane V. Hegarty, University College Cork, Ireland
Keywords: blood–brain barrier, P-glycoprotein, St. John’s wort, Alzheimer’s disease
A commentary on
Expression of tight junction and drug
efflux transporter proteins in an in vitro
model of human blood-brain barrier
Cioni C, Turlizzi E, Zanelli U, Oliveri G,
Annunziata P. Front Psychiatry (2012) 3:47.
doi: 10.3389/fpsyt.2012.00047
The blood–brain barrier (BBB) plays a fun-
damental role in the integrity of brain
homeostasis. Acute disruption and also
even slight shifting of equilibrium of struc-
tural elements or transport processes might
lead to substantial consequences, resulting
in neurological disorders (1).
There is a fundamental need for the
development and improvement of in vitro
models of the BBB in order to under-
stand the biology of these important reg-
ulatory tissues, and also to target the BBB
in new approaches to the treatment of
neurological diseases such as Alzheimer’s
disease (AD), stroke, and Parkinson’s dis-
ease (2). Capillaries were first successfully
isolated from the rat brain in 1973 (3).
Since then, a number of in vitro models
have been developed that are based on pri-
mary endothelial cells isolated from sev-
eral species, the most widely used being
rodent, porcine, or bovine cells (4), or
on immortalized human brain endothe-
lial cell lines such as hCMEC/D3 cells
(5). These monoculture systems, however,
are a rather simplified in vitro model in
that the interactions of endothelial cells
with neighboring cells of the neurovascular
unit, namely, astrocytes and pericytes, are
important for the development and main-
tenance of BBB properties (1, 6). A funda-
mental characteristic of the BBB is the for-
mation of interendothelial tight junctions,
which is indicated by high transendothelial
electrical resistance (TEER) values and the
expression of representative tight junction
proteins such as occludin (7). Furthermore,
a broad range of membrane transporters
are expressed at the BBB. ATP-binding-
cassette (ABC) efflux transporters such as
P-glycoprotein (P-gp, ABCB1) have been
identified as key elements of the BBB that
prevent many drugs and neurotoxic sub-
stances from entering the brain and that
transport toxic metabolites out of the brain
(2, 8). Astrocytes are important not only
for the development of tight junctions but
also for the up-regulation of efflux trans-
porters such as P-gp (9). The most widely
used in vitro models are based on non-
human mammalian cells. However, there
are species differences in expression lev-
els, substrate affinities, and the regulation
of relevant transporters (10). Especially for
investigating BBB alterations in the patho-
genesis of neurological diseases, the model
should mimic the characteristics of the
adult human BBB as closely as possible.
On the other hand, the model should be
reasonable in terms of cost, efficiency, and
technical requirements.
Cioni et al. have developed a unique
double compartment-model of the BBB
consisting of cerebral endothelial cells
isolated from cryopreserved human glial
tumors. The endothelial cells are isolated
together with astroglial cells from the same
specimens. Special emphasis was placed by
the authors on the activity of drug efflux
transporters such as P-gp and members
of the multidrug resistance protein- (MRP,
ABCC) family, as well as solute carrier
(SLC)-type transporters such as organic
anion-transporting polypeptides (OATPs).
Cioni et al. demonstrated that this brain
endothelium culture system mimics a phys-
iologically relevant situation, and may
therefore provide a new tool for studying
the effects of biological fluids or modulat-
ing substances at the BBB. A major advan-
tage of this system is the use of cryopre-
served material, which enables the collec-
tion of sufficient human brain endothelial
cells for investigation (11).
The role of the ABC transporters in the
pathogenesis of neurodegenerative disor-
ders such as AD has been increasingly well-
established in recent years. P-gp actively
transports the amyloid-β (Aβ) peptides
Aβ1–40 and Aβ1–42, which represent two
of the most prevalent forms of the peptide
in senile plaques and cerebral Aβ angiopa-
thy in the AD brain (12, 13). A decrease
in P-gp expression has been found in the
brains of non-demented aged humans, and
low P-gp expression was associated with
an increase in cerebral Aβ load (14, 15).
It was therefore proposed that induction
of P-gp function could restore the clear-
ance of Aβ peptides from the brain to
blood via the BBB (16). Furthermore, ani-
mal models of AD have been used to inves-
tigate the effects of pharmacological P-gp
modulation. Because of its known P-gp-
inducing effects, one potential candidate
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has been St. John’s wort (SJW). Brenn et al.
showed that mice receiving SJW extract
showed significant reductions of parenchy-
mal Aβ1–40 and 1–42 accumulation, and
significant increases in cerebrovascular P-
gp expression (17). Furthermore, studies
have revealed that specific SJW extracts
both attenuate Aβ-induced histopathologic
changes and alleviate memory impair-
ments in APP-transgenic mice. Interest-
ingly, these effects are independent of
hyperforin in the SJW, suggesting that
other components of SJW might be
involved in its beneficial effects (18). In
any case, these studies show that the induc-
tion of ABC transporters such as P-gp
may be a novel therapeutic strategy to
protect the brain from Aβ accumulation,
and thus, could impede the progression of
neurologic diseases such as AD.
In vitro models such as that described
by Cioni and colleagues may help to
reveal the underlying mechanisms by
which BBB transporters influence path-
ogenic processes, and thus, could point
the way toward more effective therapies in
humans.
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